Brokerages expect PAREXEL International Corporation (NASDAQ:PRXL) to post sales of $538.12 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for PAREXEL International Corporation’s earnings. The lowest sales estimate is $528.91 million and the highest is $549.00 million. PAREXEL International Corporation posted sales of $500.90 million in the same quarter last year, which suggests a positive year over year growth rate of 7.4%. The firm is expected to issue its next quarterly earnings results on Wednesday, October 25th.

On average, analysts expect that PAREXEL International Corporation will report full year sales of $538.12 million for the current fiscal year, with estimates ranging from $2.17 billion to $2.24 billion. For the next year, analysts anticipate that the company will report sales of $2.34 billion per share, with estimates ranging from $2.30 billion to $2.40 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that follow PAREXEL International Corporation.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. The company had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. During the same period in the prior year, the company posted $0.94 EPS.

Several research firms recently commented on PRXL. Zacks Investment Research downgraded PAREXEL International Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. BidaskClub downgraded PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and set a $88.10 target price on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Finally, Mizuho raised their target price on PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 30th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company’s stock. PAREXEL International Corporation currently has a consensus rating of “Hold” and an average price target of $75.92.

COPYRIGHT VIOLATION WARNING: “$538.12 Million in Sales Expected for PAREXEL International Corporation (PRXL) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/538-12-million-in-sales-expected-for-parexel-international-corporation-prxl-this-quarter.html.

PAREXEL International Corporation (PRXL) opened at 87.94 on Thursday. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $87.96. The firm has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.69 and a beta of 0.79. The firm has a 50 day moving average price of $87.67 and a 200-day moving average price of $77.32.

Hedge funds have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio increased its stake in shares of PAREXEL International Corporation by 4.5% in the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after buying an additional 73 shares during the period. Meadow Creek Investment Management LLC increased its stake in shares of PAREXEL International Corporation by 7.1% in the 1st quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock valued at $125,000 after buying an additional 132 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PAREXEL International Corporation by 10.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock valued at $173,000 after buying an additional 180 shares during the period. Advisor Group Inc. increased its stake in shares of PAREXEL International Corporation by 75.1% in the 2nd quarter. Advisor Group Inc. now owns 2,000 shares of the medical research company’s stock valued at $173,000 after buying an additional 858 shares during the period. Finally, Mogy Joel R Investment Counsel Inc. acquired a new stake in shares of PAREXEL International Corporation in the 2nd quarter valued at $204,000. 87.48% of the stock is owned by hedge funds and other institutional investors.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Get a free copy of the Zacks research report on PAREXEL International Corporation (PRXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.